Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:PCVXNYSE:QGENNASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$64.95+0.4%$64.77$47.88▼$107.37$3.56B0.33552,320 shs305,269 shsPCVXVaxcyte$35.84+3.1%$52.73$27.66▼$121.06$4.62B1.261.24 million shs1.58 million shsQGENQiagen$42.79+0.4%$40.16$37.63▼$49.30$9.51B0.621.12 million shs1.01 million shsRGENRepligen$137.99-1.0%$138.77$102.97▼$182.52$7.75B1.27716,981 shs975,539 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+0.37%+2.07%-0.99%-3.82%+29.85%PCVXVaxcyte+3.08%+8.08%-5.08%-61.02%-40.81%QGENQiagen+0.42%+1.11%+6.51%-3.88%+3.97%RGENRepligen-1.03%-2.50%+8.45%-17.63%-15.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.844 of 5 stars3.60.00.00.03.12.50.0PCVXVaxcyte3.0055 of 5 stars4.61.00.00.03.52.50.0QGENQiagen3.6786 of 5 stars2.23.00.04.52.71.71.3RGENRepligen4.8598 of 5 stars4.33.00.04.52.73.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.14Buy$110.6770.39% UpsidePCVXVaxcyte 3.10Buy$136.50280.86% UpsideQGENQiagen 2.30Hold$48.4213.15% UpsideRGENRepligen 2.64Moderate Buy$173.2525.55% UpsideCurrent Analyst Ratings BreakdownLatest ACLX, QGEN, PCVX, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025RGENRepligenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.004/29/2025RGENRepligenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $190.004/29/2025RGENRepligenWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$160.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/21/2025QGENQiagenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $43.004/16/2025RGENRepligenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$170.00 ➝ $150.004/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/4/2025QGENQiagenRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M33.14N/AN/A$9.97 per share6.51PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/AQGENQiagen$1.98B4.81$3.56 per share12.01$16.08 per share2.66RGENRepligen$634.44M12.21$2.57 per share53.61$35.19 per share3.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)PCVXVaxcyte-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)QGENQiagen$83.59M$0.36119.1517.392.394.23%13.92%8.40%5/7/2025 (Estimated)RGENRepligen$35.60M-$0.51N/A58.474.54-4.64%4.21%2.94%N/ALatest ACLX, QGEN, PCVX, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02N/AN/AN/AN/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84N/AN/AN/A$19.51 millionN/A5/7/2025Q1 2025QGENQiagen$0.49N/AN/AN/A$465.66 millionN/A4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/A2/20/2025Q4 2024RGENRepligen$0.41$0.44+$0.03-$0.60$167.58 million$167.55 million2/5/2025Q4 2024QGENQiagen$0.60$0.61+$0.01$0.39$518.54 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AQGENQiagenN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29PCVXVaxcyteN/A17.8817.88QGENQiagen0.383.613.09RGENRepligen0.2610.448.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%PCVXVaxcyte96.78%QGENQiagen70.00%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%PCVXVaxcyte3.10%QGENQiagen9.00%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionablePCVXVaxcyte160128.94 million120.77 millionOptionableQGENQiagen6,030222.29 million201.89 millionOptionableRGENRepligen2,02056.15 million55.36 millionOptionableACLX, QGEN, PCVX, and RGEN HeadlinesRecent News About These CompaniesRepligen Corporation (NASDAQ:RGEN) Q1 2025 Earnings Call TranscriptMay 1 at 4:00 AM | msn.comRGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff UncertaintyMay 1 at 4:00 AM | msn.com7RGEN : Deep Dive Into Repligen Stock: Analyst Perspectives...May 1 at 4:00 AM | benzinga.comWolfe Research Upgrades Repligen (NASDAQ:RGEN) to "Outperform"May 1 at 1:53 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Upgraded to "Hold" at StockNews.comApril 30 at 11:41 PM | marketbeat.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30 at 11:16 AM | gurufocus.comRepligen (RGEN) Price Target Adjusted by RBC Capital Amid Market Trends | RGEN Stock NewsApril 30 at 10:25 AM | gurufocus.comRepligen's Q1 Earnings Beat Estimates, Revenues Surge Y/YApril 30 at 10:10 AM | zacks.comFirst Light Asset Management LLC Trims Stock Position in Repligen Co. (NASDAQ:RGEN)April 30 at 8:13 AM | marketbeat.comRepligen’s Fair Valuation and Cautious Growth Outlook Lead to Hold RatingApril 30 at 6:57 AM | tipranks.comRepligen (NASDAQ:RGEN) Price Target Lowered to $190.00 at JPMorgan Chase & Co.April 30 at 4:33 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsApril 30 at 3:36 AM | msn.comRepligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 30 at 2:10 AM | gurufocus.comRepligen’s Strong Q1 Performance and Strategic Positioning Earns ‘Buy’ Rating from AnalystApril 29 at 2:10 PM | tipranks.comRepligen Corporation (RGEN) Q1 2025 Earnings Call TranscriptApril 29 at 1:18 PM | seekingalpha.comRepligen (RGEN) Tops Q1 Earnings and Revenue EstimatesApril 29 at 9:45 AM | zacks.comRepligen Non-GAAP EPS of $0.39 beats by $0.04, revenue of $169M beats by $5.25MApril 29 at 7:49 AM | seekingalpha.comRepligen Reports First Quarter 2025 Financial ResultsApril 29 at 7:30 AM | globenewswire.comNZS Capital LLC Boosts Position in Repligen Co. (NASDAQ:RGEN)April 29 at 7:21 AM | marketbeat.comT. Rowe Price Investment Management Inc. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)April 29 at 5:29 AM | marketbeat.comPinebridge Investments L.P. Boosts Stake in Repligen Co. (NASDAQ:RGEN)April 29 at 5:16 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACLX, QGEN, PCVX, and RGEN Company DescriptionsArcellx NASDAQ:ACLX$64.95 +0.24 (+0.37%) As of 04/30/2025 04:00 PM EasternArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Vaxcyte NASDAQ:PCVX$35.84 +1.07 (+3.08%) As of 04/30/2025 04:00 PM EasternVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Qiagen NYSE:QGEN$42.79 +0.16 (+0.38%) As of 04/30/2025 03:59 PM EasternQIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Repligen NASDAQ:RGEN$137.99 -1.44 (-1.03%) As of 04/30/2025 04:00 PM EasternRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
